Prognostic impact of MRD clearance timing in patients with newly diagnosed AML undergoing intensive chemotherapy

Whilst the prognostic value of MRD in AML is well established, the ideal timing for achieving undetectable MRD remains unclear.¹ The prognostic impact of MRD after induction and after subsequent chemotherapy cycles in patients with newly diagnosed AML was evaluated in a retrospective study at The University of Texas MD Anderson Cancer Center between 2010 and 2021 (N = 1,980).¹

Jen et al.¹ conducted a retrospective analysis of data from this study for patients who achieved remission with frontline intensive chemotherapy with MRD assessment following induction (TP1) and following Cycles 2 or 3 (TP2) (n = 277) to assess the relationship between MRD status at different time points and survival outcomes, and provide insights into MRD assessment timing and its implications for treatment strategies, including the potential benefit of SCT in intermediate-risk AML. Cases were grouped into MRD−/ MRD− (n = 187), MRD+/MRD− (n = 43), or MRD+/MRD+ (n = 47) at TP1 and TP2, respectively.¹ The findings were published in Blood Advances.¹